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Summary Increased vancomycin minimum inhibitory concentration (MIC) levels
in Staphylococcus aureus and their association with vancomycin treatment fail-
ure are well-known problems. Few studies have recognized progressive increases
in glycopeptide MIC levels for S. aureus strains in recent years. This study deter-
mined glycopeptide and daptomycin susceptibility among methicillin resistant S.
aureus (MRSA) strains. A total of 776 clinical isolates of MRSA recovered from 2009
to 2012 were studied for glycopeptide and daptomycin susceptibility using the E-
test method. The vancomycin MIC geometric mean (GM) of the MRSA isolates was
0.923, 0.944, 1.134 and 1.294mg/L in the years 2009, 2010, 2011 and 2012, respec-
tively, and the trend signiﬁcantly increased over the years (P < 0.0001). Similarly,
the teicoplanin MIC GM was 1.47, 1.49, 1.8 and 2.04mg/L in the years from 2009 to
2012, respectively (P < 0.0001). MIC shifts were not found for daptomycin (P > 0.232).
A signiﬁcant increase in the MIC for glycopeptides was observed among the clinical
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MRSA isolates at our center over a 4-year period. However, the daptomycin MIC did
not increase in the observed MRSA isolates.
© 2015 King Saud Bin Abdulaziz University for Health Sciences. Published by Elsevier
ed.
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was not observed for daptomycin (P > 0.232).
The MIC distributions for each drug from 2009
to 2012 are shown in Fig. 2. The most noticeableLimited. All rights reserv
Introduction
Methicillin-resistant Staphylococcus aureus (MRSA)
strains with reduced susceptibility to vancomycin
are emerging worldwide [1]. Several studies have
reported elevated vancomycin MICs in MRSA iso-
lates in which the MICs are at the upper end of
the susceptibility range [2]. Although most of these
strains have a vancomycin MIC within the suscepti-
ble range according to the Clinical and Laboratory
Standards Institute (CLSI) guidelines, some reports
have shown a universal increase in the vancomycin
MICs over time (also known as a MIC creep) [3].
Limited studies of the vancomycin MIC creep based
on routine susceptibility testing in clinical labo-
ratories are available. However, MIC creep is not
global; some centers have observed no changes
in vancomycin MICs over time [4,5]. The reports
of vancomycin MIC creep in health care settings
from different countries, including lower income
countries, such as India, are inadequate because of
insufﬁcient microbiological facilities and the cost
of MIC tests in many hospitals. This may be an
important reason for the scant data on the MIC
creeps in such countries. Several susceptibility tests
are available, but CLSI recommends MIC testing
for sensitivity to glycopeptide and daptomycin [6].
Although several MIC markers have been reported
to detect changes in the MIC, the geometric mean
MIC is considered to be a more sensitive marker [7].
The purpose of this study was to evaluate
MIC trends among clinical MRSA isolates for gly-
copeptides and daptomycin over a 4-year period
(2009—2012) by utilizing both a more sensitive MIC
testing method (E-test) and a more sensitive sus-
ceptibility marker (geometric mean) to detect MIC
changes over time.
Materials and methods
The present study was carried out in the Sanjay
Gandhi Post Graduate Institute of Medical Sciences,
Lucknow a 900 bedded tertiary care center of
North India. A total of 776 MRSA strains isolated
between 2009 and 2012 from different clinical spec-
imens, such as blood, wounds, abscesses, sputum,
urine and body ﬂuids, were subjected to glycopep-
tide and daptomycin susceptibility tests. All of the
p
t
M
isolates were stored in cryo vials at −80 ◦C until MIC
esting was performed.
The MIC tests were performed using the standard
-test (BioMerieux India Pvt Ltd) procedure. Muller
inton Agar (Oxoid Ltd., Basingstoke, Hampshire,
ngland) plates were swabbed with 0.5 McFarland
tandard suspensions of test organisms and allowed
o dry. Vancomycin, teicoplanin and daptomycin E-
trips were placed in the plates, and then, the
lates were incubated at 37 ◦C for 18 h.
MIC trends over 4 years were assessed using
non-parametric correlation (Spearman’s r) test.
ne-way analysis of variance (ANOVA) with two-
ided Bonferroni multiple comparison tests were
erformed to assess signiﬁcance. Statistical signif-
cance was deﬁned as P values <0.05. Statistical
nalyses were performed by using the Statistical
ackage for the Social Sciences version 15 (SPSS
nc., Chicago, IL).
esults
uring the study period, a total of 776 clinical
RSA isolates were collected for analysis. The
umbers of isolates tested each year were 131,
27, 207 and 211 in 2009, 2010, 2011 and 2012,
espectively. The vancomycin MIC geometric means
igniﬁcantly increased from 0.923 to 1.294mg/L
ver the study period (Fig. 1). The vancomycin
IC mode was 1.0 in 2009 but increased to 1.5
etween 2010 and 2012 (Table 1). The teicoplanin
eometric mean MIC ranged from 1.47 to 2.44mg/L
Fig. 1), and a signiﬁcant increase between 2009
nd 2012 was observed (P < 0.0001). Teicoplanin and
aptomycin MIC modes varied from 1.5 to 3.0mg/L
nd 0.75 to 0.5mg/L between 2009 and 2012,
espectively (Table 1). A decreasing tendency was
bserved for the daptomycin MIC mode. The geo-
etric mean of the daptomycin MIC ranged from
.455 to 0.430mg/L over the years, and a MIC shiftopulation shifts were seen with vancomycin and
eicoplanin (Fig. 2a and b). The shifts in vancomycin
ICs primarily occurred as a result of a decrease
n the percentage of isolates with a MIC of 1mg/L
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Table 1 Susceptibility trends among MRSA strains isolated from 2009 to 2012.
Antibiotic Year Modal MIC Median MIC Geometric mean Mean %S/%R/%I
Vancomycin 2009 0.8 1.0 0.93 1.06 100/0/0
2010 1.5 1.0 0.94 1.09 100/0/0
2011 1.5 1.0 1.13 1.2 98/0/2
2012 1.5 1.5 1.29 1.41 99/0/1
Teicoplanin 2009 1.5 1.5 1.47 2.01 100/0/0
2010 1.5 1.5 1.49 2.04 100/0/0
2011 3.0 2.0 1.8 2.56 100/0/0
2012 2.0 2.0 2.04 3.01 100/0/0
Daptomycin 2009 0.75 0.38 0.465 0.53 100/0/0
2010 0.5 0.38 0.4 0.46 100/0/0
2011 0.5 0.38 0.35 0.40 98/0/2-NS
2012 0.75 0.38
NS: non-susceptible.
Figure 1 The geometric mean± standard error of
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rhe vancomycin, teicoplanin and daptomycin MICs in
ethicillin-resistant Staphylococcus aureus isolated from
009 to 2012.
35.1% in 2009 to 20.8% in 2012) and an increase in
he percentage of isolates with a MIC of 1.5mg/L
22.1% in 2009 to 35.07% in 2012). There was no
solate with a vancomycin MIC≥ 6mg/L. Overall,
he MICs increased for vancomycin and teicoplanin
P < 0.0001) and declined slightly for daptomycin
P > 0.286) over the study period. However, 3 iso-
ates were non-susceptible to daptomycin using the
urrent CLSI guidelines, and all of them were pos-
tive for hVISA by screening methods (data not
iven).iscussion
educed susceptibility to glycopeptides in S. aureus
as been a major medical concern over the past
p
t
t
c0.43 0.33 99/0/1-NS
ecade. Previous studies have reported elevated
ancomycin MICs in MRSA isolates in which the MICs
re at the higher end of the susceptibility range
8—10]. As decreases in vancomycin susceptibility
ppear to occur, close monitoring of vancomycin
usceptibility trends is necessary, especially in
ountries where the inappropriate use of antibi-
tics is common [11] and the bacterial disease
urden is high [12]. Recently, the UK and Ireland
eported a signiﬁcant increase in vancomycin MICs
or S. aureus isolates, and the analysis was based on
he changes in the geometric mean of the MICs [2].
imilarly, in the present study, the geometric mean
or vancomycin was 0.923 in 2009 and increased to
.294 in 2012 (1.38-fold), while the teicoplanin MIC
ncreased from 1.47 in 2009 to 2.44 in 2012 (1.65-
old). Previous reports from other centers and the
SA showed a signiﬁcant increase (1.5—3.5-fold) in
he vancomycin MIC geometric means over a time
eriod [3,13]. In the present study, the daptomycin
eometric mean remained unchanged over time
nd actually declined slightly in 2012 (0.93-fold)
rom the 2009 MIC geometric mean. Consistent with
ur ﬁndings, one previous study from the USA also
evealed a 0.90-fold decrease in the daptomycin
IC geometric mean in 2007 [13]. Although there
as a decrease in the daptomycin MIC geometric
ean over the study period in our center, 3 strains
ere found to be non-susceptible to daptomycin,
nd all of these isolates were identiﬁed as hVISA.
his observation is of clinical concern and suggests
he need to monitor the emergence of resistance to
aptomycin in S. aureus strains and also highlights
he need for the judicious use of this drug to
etain its long-term effect. In accordance with
revious observations [14], we also recommend
he administration of other agents, such as dap-
omycin, linezolid and rifampicin, alone or in
ombination with vancomycin, in patients infected
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fFigure 2 The population distribution of vancomycin, teic
MIC population distribution 2009—12, b: the teicoplanin
population distribution 2009—12).
with high glycopeptide MIC strains. However,
linezolid is not licensed for the treatment of
bacteremia/infective endocarditis and daptomycin
is not used for respiratory infections [15]. The van-
comycin monitoring guidelines recommend higher
troughs (15—20g/mL) for serious infections,
such as bacteremia, endocarditis, osteomyelitis,
meningitis and hospital-acquired pneumonia,
caused by S. aureus and the use of an alternative
agent when the MIC is ≥2.0g/mL [16]. Strains
with elevated glycopeptide MICs require aggressive
vancomycin dosing to achieve troughs between
d
d
r
mnin and daptomycin from 2009 to 2012 (a: the vancomycin
opulation distribution 2009—12, c: the daptomycin MIC
5 and 20g/mL. However, therapeutic drug
onitoring of vancomycin is required to reduce the
isk of toxicity (ototoxicity and nephrotoxicity).
t has also been observed that serum unbound
ancomycin trough concentrations at 4—5 times
he MIC or a 24-h AUC/MIC ratio of 400 are optimal
or bacterial eradication and clinical success [14].
A shift in MICs over time may accelerate theevelopment of resistance because of suboptimal
rug exposure resulting from vancomycin dosing
egimens [17]. The factors involved in the develop-
ent of reduced susceptibility to vancomycin and
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[lycopeptides and daptomycin susceptibility trends
he subsequent ‘‘glycopeptide MIC creep’’ are not
ntirely known, but this phenomenon is of clinical
oncern because poorer treatment outcomes have
een associated with higher vancomycin MICs [18].
herefore, the recognition of this phenomenon is
mportant because it may be a precursor to hVISA
nd VISA. To the best of our knowledge, this is the
rst report of a daptomycin-non-susceptible hVISA
nfection in India.
onclusion
lycopeptide MIC increases within the suscep-
ible range were observed among the clinical
RSA isolates at our center over a 4-year period.
hile no daptomycin MIC creep was observed in
he MRSA isolates, the emergence of daptomycin
on-susceptible hVISA strains calls for constant
onitoring.
onﬂict of interest
ll of the authors conﬁrm that they have no conﬂict
f interest.
cknowledgements
vinash Singh acknowledges ﬁnancial assistance
rom the Indian Council of Medical Research, Gov-
rnment of India through senior research fellowship
rant No. 80/675/10-ECD-I and intramural grants
o. 2013-30-IMP-EXP/177 from SGPGIMS. Satyendra
umar Singh also acknowledges the ﬁnancial assis-
ance from the Council of Scientiﬁc and Industrial
esearch (File no- 09/590/ (0147)/ 2010-EMR-1),
ew Delhi, India.
eferences
[1] Hiramatsu K. Vancomycin-resistant Staphylococcus aureus:
a new model of antibiotic resistance. Lancet Infect Dis
2001;1:147—55.
[2] Hussain FM, Boyle-Vavra S, Shete PB, Daum RS. Evidence
for a continuum of decreased vancomycin susceptibility in
unselected Staphylococcus aureus clinical isolates. J Infect
Dis 2002;186:661—7.
[3] Wang G, Hindler JF, Ward KW, Bruckner DA. Increased van-
comycin MICs for Staphylococcus aureus clinical isolates
[
Available online at www
ScienceDong MRSA 345
from a university hospital during a 5-year period. J Clin
Microbiol 2006;44:3883—6.
[4] Fink SL, Martinello RA, Campbell SM, Murray TS. Low
prevalence of heterogeneous vancomycin-intermediate
Staphylococcus aureus isolates among Connecticut veter-
ans. Antimicrob Agents Chemother 2012;56:582—3.
[5] Holmes RL, Jorgensen JH. Inhibitory activities of 11 antimi-
crobial agents and bactericidal activities of vancomycin and
daptomycin against invasive methicillin-resistant Staphylo-
coccus aureus isolates obtained from 1999 through 2006.
Antimicrob Agents Chemother 2008;52:757—60.
[6] Performance standards for antimicrobial susceptibility test-
ing. Wayne, PA: Clinical and Laboratory Standard Institute;
2012.
[7] White RL, Kays MB, Friedrich LV, Del Bene VE. Impact
of different statistical methodologies on the evaluation
of the in-vitro MICs for Bacteroides fragilis of selected
cephalosporins and cephamycins. J Antimicrob Chemother
1993;31:57—64.
[8] Appelbaum PC. Reduced glycopeptide susceptibility in
methicillin-resistant Staphylococcus aureus (MRSA). Int J
Antimicrob Agents 2007;30:398—408.
[9] Park SY, Oh IH, Lee HJ, Ihm CG, Son JS, Lee MS, et al.
Impact of reduced vancomycin MIC on clinical outcomes
of methicillin-resistant Staphylococcus aureus bacteremia.
Antimicrob Agents Chemother 2013;57:5536—42.
10] Choi EY, Huh JW, Lim CM, Koh Y, Kim SH, Choi SH, et al.
Relationship between the MIC of vancomycin and clini-
cal outcome in patients with MRSA nosocomial pneumonia.
Intensive Care Med 2011;37:639—47.
11] Ganguly NK, Arora NK, Chandy SJ, Fairoze MN, Gill JP, Gupta
U, et al. Rationalizing antibiotic use to limit antibiotic resis-
tance in India. Indian J Med Res 2011;134:281—94.
12] World Health Statistics. France: World Health Organization;
2011.
13] Steinkraus G, White R, Friedrich L. Vancomycin MIC
creep in non-vancomycin-intermediate Staphylococcus
aureus (VISA), vancomycin-susceptible clinical methicillin-
resistant S. aureus (MRSA) blood isolates from 2001—05. J
Antimicrob Chemother 2007;60:788—94.
14] Hidayat LK, Hsu DI, Quist R, Shriner KA, Wong-Beringer
A. High-dose vancomycin therapy for methicillin-resistant
Staphylococcus aureus infections: efﬁcacy and toxicity.
Arch Intern Med 2006;166:2138—44.
15] Gould IM. Clinical relevance of increasing glycopeptide MICs
against Staphylococcus aureus. Int J Antimicrob Agents
2008;31(Suppl. 2):1—9.
16] Liu C, Bayer A, Cosgrove SE, Daum RS, Fridkin SK,
Gorwitz RJ, et al. Clinical practice guidelines by the Infec-
tious Diseases Society of America for the treatment of
methicillin-resistant Staphylococcus aureus infections in
adults and children. Clin Infect Dis 2011;52:e18—55.
17] Moise PA, Sakoulas G, Forrest A, Schentag JJ. Van-
comycin in vitro bactericidal activity and its relationship
to efﬁcacy in clearance of methicillin-resistant Staphylo-
coccus aureus bacteremia. Antimicrob Agents Chemother
2007;51:2582—6.18] Jacob JT, DiazGranados CA. High vancomycin minimum
inhibitory concentration and clinical outcomes in adults
with methicillin-resistant Staphylococcus aureus infec-
tions: a meta-analysis. Int J Infect Dis 2013;17:e93—100.
.sciencedirect.com
irect
